Literature DB >> 20444691

Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody.

Ryutaro Asano1, Keiko Ikoma, Yukiko Sone, Hiroko Kawaguchi, Shintaro Taki, Hiroki Hayashi, Takeshi Nakanishi, Mitsuo Umetsu, Yu Katayose, Michiaki Unno, Toshio Kudo, Izumi Kumagai.   

Abstract

We previously reported the utility for cancer immunotherapy of a humanized bispecific diabody (hEx3) that targets epidermal growth factor receptor and CD3. Here, we used dynamic and static light scattering measurements to show that the multimer fraction observed in hEx3 in solution is a monodisperse tetramer. The multimerization into tetramers increased the inhibition of cancer cell growth by the hEx3 diabody. Furthermore, 1:2 stoichiometric binding for both antigens was observed in a thermodynamic analysis, indicating that the tetramer has bivalent binding activity for each target, and the structure may be in a circular configuration, as is the case for the single-chain Fv tetrabody. In addition to enhanced cytotoxicity, the functional affinity and stability of the hEx3 tetrabody were superior to those of the hEx3 diabody. The increase in molecular weight is also expected to improve the pharmacokinetics of the bispecific diabody, making the hEx3 tetrabody attractive as a therapeutic antibody fragment for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444691      PMCID: PMC2898345          DOI: 10.1074/jbc.M110.120444

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.

Authors:  S M Kipriyanov; G Moldenhauer; J Schuhmacher; B Cochlovius; C W Von der Lieth; E R Matys; M Little
Journal:  J Mol Biol       Date:  1999-10-15       Impact factor: 5.469

2.  Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.

Authors:  Ryutaro Asano; Yukiko Sone; Koki Makabe; Kouhei Tsumoto; Hiroki Hayashi; Yu Katayose; Michiaki Unno; Toshio Kudo; Izumi Kumagai
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

3.  Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers.

Authors:  A M Wu; W Chen; A Raubitschek; L E Williams; M Neumaier; R Fischer; S Z Hu; T Odom-Maryon; J Y Wong; J E Shively
Journal:  Immunotechnology       Date:  1996-02

4.  Rapid measurement of binding constants and heats of binding using a new titration calorimeter.

Authors:  T Wiseman; S Williston; J F Brandts; L N Lin
Journal:  Anal Biochem       Date:  1989-05-15       Impact factor: 3.365

5.  Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.

Authors:  Bernd Schlereth; Iduna Fichtner; Grit Lorenczewski; Petra Kleindienst; Klaus Brischwein; Antonio da Silva; Peter Kufer; Ralf Lutterbuese; Ilse Junghahn; Sabine Kasimir-Bauer; Pauline Wimberger; Rainer Kimmig; Patrick A Baeuerle
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

6.  A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.

Authors:  M A Arndt; J Krauss; S M Kipriyanov; M Pfreundschuh; M Little
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

7.  Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.

Authors:  Lillian S Shahied; Yong Tang; R Katherine Alpaugh; Robert Somer; Dana Greenspon; Louis M Weiner
Journal:  J Biol Chem       Date:  2004-10-07       Impact factor: 5.157

8.  Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.

Authors:  Ryutaro Asano; Yasuhiro Watanabe; Hiroko Kawaguchi; Hidesuke Fukazawa; Takeshi Nakanishi; Mitsuo Umetsu; Hiroki Hayashi; Yu Katayose; Michiaki Unno; Toshio Kudo; Izumi Kumagai
Journal:  J Biol Chem       Date:  2007-07-19       Impact factor: 5.157

9.  Crystal structure of a diabody, a bivalent antibody fragment.

Authors:  O Perisic; P A Webb; P Holliger; G Winter; R L Williams
Journal:  Structure       Date:  1994-12-15       Impact factor: 5.006

10.  A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.

Authors:  P Bühler; P Wolf; D Gierschner; I Schaber; A Katzenwadel; W Schultze-Seemann; U Wetterauer; M Tacke; M Swamy; W W A Schamel; U Elsässer-Beile
Journal:  Cancer Immunol Immunother       Date:  2007-06-20       Impact factor: 6.968

View more
  9 in total

1.  Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Ippei Shimomura; Shintaro Taki; Takeshi Nakanishi; Mitsuo Umetsu; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

2.  Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells.

Authors:  Ryutaro Asano; Yuri Kuroki; Sachiko Honma; Mihoko Akabane; Shunsuke Watanabe; Shinzo Mayuzumi; Shuichi Hiyamuta; Izumi Kumagai; Koji Sode
Journal:  MAbs       Date:  2018-07-09       Impact factor: 5.857

3.  A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.

Authors:  Diane L Rossi; Edmund A Rossi; Thomas M Cardillo; David M Goldenberg; Chien-Hsing Chang
Journal:  MAbs       Date:  2013-12-02       Impact factor: 5.857

4.  Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.

Authors:  Ryutaro Asano; Ippei Shimomura; Shota Konno; Akiko Ito; Yosuke Masakari; Ryota Orimo; Shintaro Taki; Kyoko Arai; Hiromi Ogata; Mai Okada; Shozo Furumoto; Masayoshi Onitsuka; Takeshi Omasa; Hiroki Hayashi; Yu Katayose; Michiaki Unno; Toshio Kudo; Mitsuo Umetsu; Izumi Kumagai
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

5.  Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life.

Authors:  Ryutaro Asano; Noriaki Koyama; Yasuyo Hagiwara; Yosuke Masakari; Ryota Orimo; Kyoko Arai; Hiromi Ogata; Shozo Furumoto; Mitsuo Umetsu; Izumi Kumagai
Journal:  FEBS Open Bio       Date:  2016-05-16       Impact factor: 2.693

6.  A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity.

Authors:  Aruto Sugiyama; Mitsuo Umetsu; Hikaru Nakazawa; Teppei Niide; Tomoko Onodera; Katsuhiro Hosokawa; Shuhei Hattori; Ryutaro Asano; Izumi Kumagai
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

7.  Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity.

Authors:  Ryutaro Asano; Keisuke Nagai; Koki Makabe; Kento Takahashi; Takashi Kumagai; Hiroko Kawaguchi; Hiromi Ogata; Kyoko Arai; Mitsuo Umetsu; Izumi Kumagai
Journal:  Oncotarget       Date:  2018-02-14

8.  Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface.

Authors:  Jin Hong Kim; Dong Hyun Song; Suk-Jun Youn; Ji Won Kim; Geunyoung Cho; Sun Chang Kim; Hayyoung Lee; Mi Sun Jin; Jie-Oh Lee
Journal:  Sci Rep       Date:  2016-09-29       Impact factor: 4.379

9.  Build-up functionalization of anti-EGFR × anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats.

Authors:  Ryutaro Asano; Katsuhiro Hosokawa; Shintaro Taki; Shota Konno; Ippei Shimomura; Hiromi Ogata; Mai Okada; Kyoko Arai; Masayoshi Onitsuka; Takeshi Omasa; Takeshi Nakanishi; Mitsuo Umetsu; Izumi Kumagai
Journal:  Sci Rep       Date:  2020-03-18       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.